ERBA Diagnostics, Inc.
ERBA Diagnostics, Inc. Announces Notice of Noncompliance With NYSE MKT Continued Listing Standards
MIAMI, Dec. 1, 2015 (GLOBE NEWSWIRE) -- ERBA Diagnostics, Inc. (NYSE MKT:ERB) (the "Company"), a fully integrated in vitro diagnostics company, announced today that, on November 25, 2015, the Company received a letter from NYSE MKT LLC (the "Exchange") stating that the Exchange has determined that the Company is not in compliance with Sections 134 and 1101 of the Exchange's Company Guide (the "Company Guide") due to the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 with the Securities and Exchange Commission (the "SEC"). The letter also states that the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 is a material violation of its listing agreement with the Exchange and, therefore, pursuant to Section 1003(d) of the Company Guide, the Exchange is authorized to suspend and, unless prompt corrective action is taken, remove the Company's securities from the Exchange.